RaQualia looks to progress lead EP4 inhibitor on back of Aratana deal
This article was originally published in Scrip
Pfizer Japan spin-out RaQualia Pharma expects a new active pharmaceutical ingredient (API) development agreement with the private US firm Aratana Therapeutics to help progress the development of one of its most advanced pipeline candidates.
You may also be interested in...
Novel antibody-drug conjugate receives approval in Japan for second-line breast cancer, providing another push to Japanese firm’s strategic plan to build up its oncology operations.
Collaboration with fundraising Tokyo-based venture builds mid-sized firm's interest in cell-based therapies in a highly supportive regulatory environment.
New long-term clinical data with Takeda’s dengue vaccine contender show a durable response against all four serotypes and support the dosing regimen in an ongoing pivotal study.